



**NEWS ANNOUNCEMENT**  
**CONTACT: Robin Baum at 440-392-7428**

**FOR IMMEDIATE RELEASE**

**STERIS CORPORATION LAUNCHES THE NEW RELIANCE® 680PG  
PHARMACEUTICAL GRADE WASHER GLOBALLY**  
*New washing system provides an advanced level of cleaning assurance*

**MENTOR, OHIO – June 1, 2009** – The pharmaceutical manufacturing industry is under pressure more than ever before to improve their processes and cost effectiveness. They require equipment that can help them shorten their validation time, comply with standards and guidelines, and reduce their total cost of ownership. STERIS Corporation has added the Reliance 680PG Pharmaceutical Grade Washer, an advanced high-performance system, to its line of pharmaceutical-grade washing systems to help its pharmaceutical Customers better address their specific automated washing needs.

“Our new STERIS washing solution offers several innovative features that are designed to provide an even higher level of assurance of consistent cleaning results,” comments Marcel Dion, senior product manager for STERIS. “For example, the new total organic carbon (TOC) monitoring system verifies the presence of residual detergent or soil in the final rinse water, which provides a higher level of assurance that the load items have been properly cleaned and rinsed. This new system also has chamber spray arms whose rotation can be monitored to ensure constant and complete spray coverage of all the items in the load.”

The new Reliance 680PG system complies with the ASME BPE 2007 (Bio Processing Equipment) standard, which relates to the requirements applicable to system design for bioprocessing, pharmaceutical and personal care product industries. The 680PG washer was also designed to minimize its impact on the environment. The system can use re-circulated chilled water to cool down the effluent, which saves 36 gallons (136L) of valuable cold water during each heated cycle phase.

The Reliance 680PG Pharmaceutical Grade Washer also offers facilities extraordinary process flexibility. An extensive line of modular loading accessories is easy to configure with the system, and the washer can be built with either a Siemens or Allen-Bradley programmable logic controller.\*

The mission of STERIS Corporation is to provide a healthier today and safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products and services. The Company's more than 5,000 dedicated employees around the

**STERIS Corporation**  
**News Announcement**  
**Page 2**

world work together to supply a broad array of equipment, consumables and services solutions to healthcare, pharmaceutical, industrial and government customers. The Company is listed on the New York Stock Exchange under the symbol STE. For more information, visit [www.steris.com](http://www.steris.com).

*\*Siemens and Allen Bradley are registered trademarks of Siemens AG and Rockwell Automation, respectively.*

Editor's Note:

For more information about this and other STERIS pharmaceutical technologies, please visit [www.steris.com](http://www.steris.com) and select the "Pharmaceutical Manufacturing" home page.

#####

*This news release may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to the Company or its industry that are intended to qualify for the protections afforded "forward-looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this report, and may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "targets," "forecasts," "confidence," and "seeks," or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, and changes in government regulations or the application or interpretation thereof. Other risk factors are described in the Company's Form 10-K and other securities filings. Many of these important factors are outside STERIS's control. No assurances can be provided as to any level of share repurchases, earnings and revenue trends, expense reduction or other future financial results. Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, (a) the potential for increased pressure on pricing that leads to erosion of profit margins, (b) the possibility that market demand will not develop for new technologies, products or applications, or the Company's business initiatives will take longer, cost more or produce lower benefits than anticipated, (c) the possibility that application of or compliance with laws, court rulings, regulations, regulatory actions, including without limitation the previously disclosed FDA warning letter, certifications or other requirements or standards may delay or prevent new product introductions, affect the production and marketing of existing products, or otherwise affect Company performance, results, or value, (d) the potential of international unrest or effects of fluctuations in currencies, tax assessments or rates, raw material costs, benefit or retirement plan costs, or other regulatory compliance costs, (e) the possibility of reduced demand, or reductions in the rate of growth in demand, for the Company's products and services, and (f) the possibility that anticipated cost savings may not be achieved, or that transition, labor, competition, timing, execution, regulatory, governmental, or other issues or risks associated with the matters described in this release may adversely impact Company performance, results, or value.*